Martingale Asset Management L P Has $12.88 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Martingale Asset Management L P cut its Pfizer stake by 9.7%, selling 54,600 shares to hold 505,608 shares worth $12.88 million per its latest 13F filing.
• Pfizer beat Q4 estimates with EPS $0.66 (vs. $0.57) and $17.56B revenue; the stock trades near $26.85 and carries an analyst consensus of "Hold" with an average target of $28.05.
• Recent positive catalysts—China approval of its GLP‑1 weight drug, promising Phase 2 eczema data for tilrekimig, progress on an early‑stage oncology candidate, and a next‑gen pneumococcal vaccine—could boost growth, though valuation and post‑pandemic pipeline concerns weigh on sentiment.

Martingale Asset Management L P cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 505,608 shares of the biopharmaceutical company's stock after selling 54,600 shares during the quarter. Martingale Asset Management L P's holdings in Pfizer were worth $12,883,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in PFE. Acorns Advisers LLC boosted its stake in Pfizer by 15.9% in the third quarter. Acorns Advisers LLC now owns 14,492 shares of the biopharmaceutical company's stock valued at $369,000 after acquiring an additional 1,989 shares during the last quarter. Invesco Ltd. lifted its position in Pfizer by 3.7% during the 3rd quarter. Invesco Ltd. now owns 30,335,842 shares of the biopharmaceutical company's stock valued at $772,957,000 after purchasing an additional 1,085,701 shares during the period. Seven Mile Advisory lifted its stake in shares of Pfizer by 34.0% in the third quarter. Seven Mile Advisory now owns 12,614 shares of the biopharmaceutical company's stock valued at $321,000 after buying an additional 3,200 shares in the last quarter. Employees Retirement System of Texas lifted its stake in shares of Pfizer by 200.9% in the 3rd quarter. Employees Retirement System of Texas now owns 212,310 shares of the biopharmaceutical company's stock worth $5,410,000 after purchasing an additional 141,744 shares during the period. Finally, Sei Investments Co. lifted its holdings in Pfizer by 9.7% in the 3rd quarter. Sei Investments Co. now owns 2,890,092 shares of the biopharmaceutical company's stock valued at $73,640,000 after purchasing an additional 254,401 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PFE shares. Bank of America reduced their price target on shares of Pfizer from $29.00 to $28.00 and set a "neutral" rating for the company in a research report on Monday, December 15th. HSBC reissued a "buy" rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. UBS Group began coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a "neutral" rating and a $25.00 price objective for the company. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, TD Cowen restated a "hold" rating on shares of Pfizer in a report on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $28.05.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight management drug Xianweiying for long‑term weight management in adults — opens a large new market and adds a growth vector vs. GLP‑1 competitors. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Tilrekimig (trispecific antibody) reported encouraging Phase 2 eczema results — if confirmed in later‑stage trials this could meaningfully boost Pfizer’s immunology franchise and long‑term growth profile. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), adding to the company’s cancer pipeline and optionality. Early trials expand long‑term R&D upside. Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline
• Positive Sentiment: Completed Phase 2 toddler study for a next‑gen pneumococcal vaccine — progress here supports potential future vaccine launches and pediatric franchise strength. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Market/sector roundups and commentary mention Pfizer among peers but provide no immediate catalyst. Useful for context but unlikely to move the stock alone. Health Care Roundup: Market Talk
• Neutral Sentiment: Executive commentary on navigating regulatory uncertainty highlights Pfizer’s regulatory expertise — background support but not an earnings driver. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Coverage notes Pfizer has dipped more than the broader market, reflecting short‑term underperformance and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
• Negative Sentiment: Analyses questioning Pfizer’s valuation and post‑pandemic growth (patent cliffs, pipeline risks) continue to pressure sentiment — these narratives can cap multiple expansion until clearer revenue drivers emerge. Pfizer: Cheap For A Reason
• Negative Sentiment: Valuation/longer‑term value debates persist in recent pieces weighing pandemic sales declines and patent concerns against future pipeline gains. Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns

Pfizer Stock Down 1.7%

Shares of NYSE:PFE opened at $26.85 on Friday. The company has a 50 day moving average of $26.47 and a 200-day moving average of $25.51. The stock has a market cap of $152.65 billion, a price-to-earnings ratio of 19.74 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. During the same period in the prior year, the firm posted $0.63 EPS. The business's quarterly revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.